

Type 1 Diabetes: Current Challenges in Insulin Delivery and Monitoring

Priyanka Sharma*

Department of Biotechnology, Kalinga Institute of Industrial Technology, India

Introduction

Type 1 diabetes (T1D) is a chronic autoimmune condition where the body's immune system attacks and destroys insulin-producing beta cells in the pancreas. As a result, individuals with T1D must rely on exogenous insulin to regulate blood glucose levels. The management of T1D has significantly improved over the past few decades, with advancements in insulin therapy and monitoring technologies. However, achieving optimal blood glucose control remains challenging due to issues surrounding insulin delivery methods, monitoring accuracy, and the complexities of individualized treatment. This article explores the current challenges in insulin delivery and monitoring for people with T1D, and highlights potential solutions that may pave the way for more effective management.

Description

Challenges in insulin delivery

The primary challenge in the management of T1D is the precise delivery of insulin. Insulin must be administered in a manner that closely mimics the body's natural insulin production, which is complex and variable throughout the day. The traditional approach of insulin injections (either subcutaneous injections or insulin pens) has limitations that can make consistent blood glucose control difficult [1].

Inconsistent absorption of insulin: Insulin injections are administered subcutaneously, and the absorption rate can vary depending on the injection site, the individual's body composition, and even the insulin formulation used. This variability can lead to fluctuations in blood sugar levels, making it difficult for people with T1D to achieve optimal control [2].

Insulin pump therapy: Insulin pumps deliver insulin continuously through a small catheter inserted under the skin. While pumps provide more precise and flexible insulin delivery compared to injections, they come with their own set of challenges [3]. These devices require regular maintenance, including changing infusion sets and reservoirs, and users need to learn how to program and manage pump settings for different situations, such as exercise or meals. Moreover, insulin pumps are also prone to mechanical issues, and issues like tubing blockages or infusion site infections can disrupt the delivery process.

Difficulty in matching insulin doses to variable needs: One of the greatest challenges in insulin therapy is accurately matching insulin doses to an individual's needs. These needs fluctuate throughout the day based on factors such as food intake, physical activity, stress, illness, and even hormonal changes. Insulin sensitivity can change throughout the day or season, making it difficult to determine the correct amount of insulin needed at any given time [4].

Closed-loop systems: Closed-loop insulin delivery systems, also known as artificial pancreas systems, aim to automate insulin delivery by combining continuous glucose monitoring (CGM) with an insulin pump. While promising, these systems are still evolving and face challenges in maintaining optimal blood glucose levels, particularly

during periods of physical activity or when glucose levels are rapidly changing.

Challenges in blood glucose monitoring

Continuous and accurate blood glucose monitoring is essential for managing T1D, yet the current methods face significant challenges.

Fingerstick glucose monitoring: Traditional blood glucose meters require individuals with T1D to perform frequent fingerstick tests. While these devices provide immediate results, they are invasive, inconvenient, and can be painful [5]. Moreover, they only provide a snapshot of blood glucose at the time of testing and do not provide continuous data that is essential for fine-tuning insulin therapy.

Continuous glucose monitoring (CGM): CGM devices, which measure glucose levels continuously throughout the day via a sensor placed under the skin, have become a valuable tool for managing T1D. However, CGMs are not without their limitations [6]. Sensors must be replaced every few days, and the accuracy of CGM devices can be affected by factors such as sensor calibration, sensor placement, and hydration levels. Although CGMs have shown improvements in their accuracy over time, there can still be discrepancies between sensor readings and actual blood glucose levels, particularly during periods of rapid glucose changes.

Calibration and accuracy: The need for calibration of CGM devices with fingerstick tests has been a barrier to seamless monitoring. Although some newer CGM systems offer "factory calibration," the issue of accuracy still persists, especially in extreme glucose ranges (both high and low). Inaccurate readings can result in inappropriate insulin adjustments, leading to hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar), both of which can be dangerous [7].

Interference and sensor lifespan: Interference from various factors, such as medications, skin conditions, or physical activity, can affect the performance of CGM sensors. Additionally, sensor lifespan can be limited to a few days, requiring frequent replacements and raising the overall cost of continuous glucose monitoring for people with T1D. While research is underway to develop sensors that last longer, these devices remain an ongoing expense for many patients.

Integration and data overload: As insulin delivery systems and

*Corresponding author: Priyanka Sharma, Department of Biotechnology, Kalinga Institute of Industrial Technology, India, E-mail: priya_sh@gmail.com

Received: 03-Dec-2024, Manuscript No: jowt-25-157834, **Editor assigned:** 05-Dec-2024, Pre QC No: jowt-25-157834(PQ), **Reviewed:** 19-Dec-2024, QC No: jowt-25-157834, **Revised:** 23-Dec-2024, Manuscript No: jowt-25-157834(R) **Published:** 30-Dec-2024, DOI: 10.4172/2165-7904.1000759

Citation: Priyanka S (2024) Type 1 Diabetes: Current Challenges in Insulin Delivery and Monitoring. J Obes Weight Loss Ther 14: 759.

Copyright: © 2024 Priyanka S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

glucose monitors become more sophisticated, the amount of data generated increases substantially [8]. While real-time glucose data is invaluable, many individuals with T1D can find the volume of information overwhelming. Additionally, the integration of data from various devices (insulin pumps, CGMs, and mobile apps) remains a challenge, and there is a need for more streamlined, user-friendly systems that allow patients to easily interpret and act on their data.

Conclusion

Despite the advancements in insulin delivery and glucose monitoring technologies, managing Type 1 diabetes continues to pose significant challenges. Variability in insulin absorption, difficulty in matching insulin doses to changing needs, and limitations in the accuracy and reliability of glucose monitoring devices are just a few of the issues that individuals with T1D face daily. However, there is considerable progress in the development of newer insulin delivery systems, such as closed-loop pumps, and more accurate, longer-lasting continuous glucose monitors. These innovations are likely to improve the quality of life for individuals with T1D and help them achieve better blood glucose control.

Acknowledgement

None

Conflict of Interest

None

References

1. Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, et al. (2016) Diagnostic accuracy of body mass index to identify obesity in older adults: NHANES 1999-2004. *Int J Obes (Lond)* 40: 761-767.
2. Douketis JD, Macie C, Thabane L, Williamson DF (2005) Systematic review applicability to clinical practice. *Int J Obes (Lond)* 29: 1153-1167.
3. Bray GA, Fruhbeck G, Ryan DH, Wilding JP (2016) Management of obesity. *Lancet* 387: 1947-1956.
4. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, et al. (2015) Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 100: 342-362.
5. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, et al. (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocr Pract Suppl* 3: 1-203.
6. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, et al. (2013) A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). *Obesity (Silver Spring)* 21: 935-943.
7. of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care* 34: 1481-1486.
8. Kushner RF, Ryan DH (2014) Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews. *JAMA* 312: 943-952.